

## Editorial

# New Enzymes as Potential Therapeutic Targets for Trypanosomiasis and Leishmaniasis

**Claudio Alejandro Pereira,<sup>1</sup> Ariel Mariano Silber,<sup>2</sup> and Elena Gonzalez-Rey<sup>3</sup>**

<sup>1</sup>Department of Molecular Biology of *Trypanosoma cruzi*, Instituto de Investigaciones Medicas Alfredo Lanari (IDIM, UBA-CONICET), Avenida Combatientes de Malvinas 3150, 1427 Buenos Avies, Argentina

<sup>2</sup>Instituto de Ciencias Biomedicas, Universidade de São Paulo, Av. Lineu Prestes 1374, Cidade Universitária Butanta, São Paulo, CEP 05508-900, Brazil

<sup>3</sup>Departamento Biología Celular e Inmunología, Instituto de Parasitología y Biomedicina "Lopez-Neyra", Avenida Conocimiento S/N, Parque Tecnológico Ciencias de la Salud, 18100 Armilla, Granada, Spain

Correspondence should be addressed to Claudio Alejandro Pereira, cpereira@retina.ar

Received 4 December 2011; Accepted 4 December 2011

Copyright © 2011 Claudio Alejandro Pereira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infections caused by the protozoan parasites *Trypanosoma cruzi*, *Trypanosoma brucei*, and *Leishmania* spp. are among the most relevant public health problems in the developing countries. Furthermore, climatic changes and migratory fluxes of the human population are broadening the former geographic restrictions of most of these diseases. Only a few therapeutic treatments are available for these infections, and main drawbacks of drugs in use are their low efficiency, high toxicity, and the emergence of strains resistant to available treatments. All these facts make the research on new drug targets and strategies for developing new drug therapeutic strategies a relevant issue.

In this special issue, we presented original research papers and reviews on the discovery of novel enzyme targets which contributed to having a picture of the state of the art on trypanosomatids' enzymes research oriented to therapeutic applications. The topics addressed in this special edition include a wide variety of enzymes and metabolic pathways: biosynthesis of galactofuranose (M. Oppenheimer et al.), prereplication machinery (S. G. Calderano et al.), glutamate metabolism (A. Magdaleno et al.), ornithine decarboxylases (J. J. Barclay et al.), sphingolipid biosynthetic (C. M. Koeller and N. Heise), phosphotransferase enzymes involved in cell energy management (C. A. Pereira et al.), Heme metabolic pathway (K. E. J. Tripodi et al.), phospholipases A (M. L. Belaunzaran et al.), topoisomerases (B. Banerjee et al.), P4 Nucleases (L. Rahbarnia et al.), enolases (L. Avilan et al.)

and in silico prediction of drug targets by non-homologous isofunctional enzymes analysis (M. Rajao Gomes et al.).

I hope the information in this special issue will be useful not only for scientists in the area, but also as a status report on this critical issue for developing countries.

Claudio Alejandro Pereira  
Ariel Mariano Silber  
Elena Gonzalez-Rey